Taking on Zaire ebolavirus

How science and innovation fuel our efforts to help combat a rare but potentially deadly disease

April 11, 2024

Share this article


Taking on Ebola
Assets / Buttons / UI / Play Button / Large clear hover

Patients inspire us to pursue the best science in our inventions and everything we do. Every innovation has the potential to help build a healthier, more hopeful future for people everywhere — which means taking on some of today’s global health challenges, including Ebola.

Leading the effort to combat Zaire ebolavirus

Our company is a health care leader in the fight against Zaire ebolavirus. Along with external collaborators from all sectors, our scientists are at the forefront of the response to outbreaks of this potentially deadly disease as we continue to help address this global health challenge. Zaire ebolavirus has had a devastating impact on the world and has proved itself to be a potentially deadly and contagious disease, with a survival rate of 50%. While there are six identified Ebola virus species, the Zaire ebolavirus strain has been the leading cause of outbreaks over the last 20 years.

Global public health preparedness against future Zaire ebolavirus outbreaks requires advanced planning, system readiness for rapid deployment and collaboration and partnership between public and private entities around the world. Our partnerships with the World Health Organization (WHO) and other health partners around the globe are a crucial component of our commitment to helping save and improve lives.

“We take Zaire ebolavirus outbreaks very seriously and act with the utmost urgency to support response efforts,” said Rachael Bonawitz, clinical director, clinical research vaccines. “Our teams are dedicated to supporting the frontline workers whose brave actions are critical in outbreak response efforts.”

In 2021, we established an agreement with UNICEF to create the world’s first global Ebola Zaire stockpile, the result of breakthrough innovation and collaboration with four leading international health and humanitarian organizations across the world. The global stockpile offers a critical, rapid-response tool.

“It has been our honor to collaborate with WHO, Gavi, UNICEF, the U.S. government and many others in supporting outbreak preparedness and response efforts,” said Drew Otoo, president of global vaccines. “Through these collaborations, we demonstrate what’s possible when partners come together to pursue a common purpose for patients.”

This level of collaboration continues to be needed for Zaire ebolavirus and other diseases. We remain committed to working in collaboration with global and local health partners to support current and future outbreak response efforts.